GleamWall
中文EN

SLN Silence Therapeutics plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1479615

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-98.2%
TTM net income YoY20.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin95.0%
Operating margin-12,343.6%
Net margin-11,276.5%
FCF margin-9,681.6%
EBITDA margin-12,279.2%

Returns

ROE-35.6%
ROA-24.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.6%
Debt / equity0.00x
Current ratio23.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$422,000$34,000$159,000$224,000$142,000$25.30M
Cost of revenue$0$0$11,000$12,000$64,000$85,000$54,000$2.04M
Gross profit$0$0$411,000$22,000$95,000$139,000$88,000$23.27M
R&D expense$9.30M$9.15M$9.12M$8.75M$20.54M$17.65M$20.81M$22.08M
SG&A expense$4.92M$4.72M$7.03M$3.73M$5.79M$5.13M$7.68M$5.54M
Operating income-$14.22M-$13.87M-$15.74M-$12.46M-$26.24M-$23.96M-$28.41M-$4.35M
Pretax income-$12.43M-$12.27M-$14.96M-$11.77M-$20.96M-$27.34M-$28.53M$12.63M
Income tax$0$1,000$0$0$1,000$10,000$0$324,000
Net income-$12.43M-$12.27M-$14.96M-$11.77M-$20.96M-$27.35M-$28.53M$12.30M
EBITDA-$14.15M-$13.79M-$15.66M-$12.38M-$26.16M-$23.88M-$28.34M-$4.28M
EPS (basic)-0.08-0.09-0.11—-0.15-0.19-0.20—
EPS (diluted)-0.08-0.09-0.11—-0.15-0.19-0.20—
Weighted avg. shares (diluted)165.60M141.71M141.70M—141.70M141.70M141.68M—
Balance sheet
Cash & equivalents$247.66M$72.05M$5.66M$11.28M$82.03M$41.74M$64.89M$121.33M
Short-term investments$0$0$64.42M$73.84M$20.16M$72.42M$71.65M$26.00M
Receivables——$0$0$28,000$85,000$41,000$972,000
Current assets$269.58M$94.28M$102.85M$118.66M$133.63M$148.55M$169.79M$187.37M
PP&E, net$1.22M$1.32M$1.40M$1.58M$1.66M$1.77M$1.69M$1.82M
Goodwill$10.25M$10.32M$10.36M$10.62M$10.62M$10.62M$10.62M$9.39M
Intangibles———$288,000———$312,000
Total assets$281.50M$106.41M$115.12M$131.44M$146.79M$165.23M$185.30M$202.63M
Current liabilities$11.26M$12.71M$10.46M$13.61M$17.38M$14.77M$19.26M$16.82M
Total liabilities$66.48M$67.94M$65.72M$69.14M$72.73M$71.08M$72.56M$68.61M
Shareholders' equity$215.02M$38.47M$49.40M$62.30M$74.06M$94.16M$112.74M$134.02M
Shares outstanding186.61M141.74M141.70M141.70M141.70M141.70M141.69M141.67M
Cash flow statement
Operating cash flow-$12.78M$1.52M-$15.60M-$17.29M-$10.89M-$21.78M-$12.31M-$27.48M
Capital expenditure$0$0$0$0$3,000$48,000$4,000$62,000
Free cash flow-$12.78M$1.52M-$15.60M-$17.29M-$10.89M-$21.83M-$12.31M-$27.54M
Investing cash flow$0$64.94M$10.00M-$53.34M$51.29M-$1.56M-$44.38M$66.12M
Financing cash flow$188.33M$2,000$0$0$0$1,000$14,000-$98,000
Depreciation & amortization$72,000$73,000$72,000$77,000$81,000$81,000$73,000$76,000
Stock-based compensation$777,000$1.31M$2.45M-$86,000$2.54M$2.08M$3.54M$3.98M

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.